Comprehensive Identification of Mutations Responsible for Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA)-to-VISA Conversion in Laboratory-Generated VISA Strains Derived from hVISA Clinical Strain Mu3
出版年份 2013 全文链接
标题
Comprehensive Identification of Mutations Responsible for Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA)-to-VISA Conversion in Laboratory-Generated VISA Strains Derived from hVISA Clinical Strain Mu3
作者
关键词
-
出版物
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 57, Issue 12, Pages 5843-5853
出版商
American Society for Microbiology
发表日期
2013-09-10
DOI
10.1128/aac.00425-13
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Mutation in the PP2C Phosphatase Gene in a Staphylococcus aureus USA300 Clinical Isolate with Reduced Susceptibility to Vancomycin and Daptomycin
- (2012) Karla D. Passalacqua et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Curing bacteria of antibiotic resistance: reverse antibiotics, a novel class of antibiotics in nature
- (2012) Keiichi Hiramatsu et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Complete Genome Sequence of Staphylococcus aureus M013, a pvl-Positive, ST59-SCCmec Type V Strain Isolated in Taiwan
- (2012) T.-W. Huang et al. JOURNAL OF BACTERIOLOGY
- Structure and function of cytidine monophosphate kinase from Yersinia pseudotuberculosis, essential for virulence but not for survival
- (2012) N. J. Walker et al. Open Biology
- Genetic Pathway in Acquisition and Loss of Vancomycin Resistance in a Methicillin Resistant Staphylococcus aureus (MRSA) Strain of Clonal Type USA300
- (2012) Susana Gardete et al. PLoS Pathogens
- walKandclpPMutations Confer Reduced Vancomycin Susceptibility inStaphylococcus aureus
- (2011) Mitsutaka Shoji et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutation of RNA Polymerase β Subunit (rpoB) Promotes hVISA-to-VISA Phenotypic Conversion of Strain Mu3
- (2011) Miki Matsuo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of rpoB Mutations on Reduced Vancomycin Susceptibility in Staphylococcus aureus
- (2011) Yukiko Watanabe et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Evolution of Multidrug Resistance during Staphylococcus aureus Infection Involves Mutation of the Essential Two Component Regulator WalKR
- (2011) Benjamin P. Howden et al. PLoS Pathogens
- An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and Vancomycin in Staphylococcus aureus
- (2010) L. Cui et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Shuttle Vectors Derived from pN315 for Study of Essential Genes in Staphylococcus aureus
- (2010) Miki Matsuo et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications
- (2010) B. P. Howden et al. CLINICAL MICROBIOLOGY REVIEWS
- Tricarboxylic Acid Cycle-Dependent Synthesis of Staphylococcus aureus Type 5 and 8 Capsular Polysaccharides
- (2010) M. R. Sadykov et al. JOURNAL OF BACTERIOLOGY
- Teichoic acids are temporal and spatial regulators of peptidoglycan cross-linking in Staphylococcus aureus
- (2010) M. L. Atilano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Contribution of vraSR and graSR Point Mutations to Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus
- (2009) L. Cui et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The First Vancomycin-Intermediate Staphylococcus aureus Strains Isolated from Patients in Thailand
- (2009) A. Lulitanond et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Genomic Analysis Reveals a Point Mutation in the Two-Component Sensor Gene graS That Leads to Intermediate Vancomycin Resistance in Clinical Staphylococcus aureus
- (2008) B. P. Howden et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Identification of the First Vancomycin Intermediate-Resistant Staphylococcus aureus (VISA) Isolate from a Hospital in Portugal
- (2008) S. Gardete et al. Microbial Drug Resistance
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started